Items Tagged ‘COMETRIQ’

October 15th, 2015

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer


According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared to Afinitor® (everolimus) in patients with advanced kidney cancer whose cancer has progressed following VEGRF-targeted therapy. Each year in the United States, more than 58,000 people are […]

View full entry

Tags: afinitor, cabozantinib, COMETRIQ, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, VEGFR-targeted agents